ReviewBiologics : targets & therapy2026

First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect Comparison.

Yi Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.